Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 12/20 | 0.52 |
| ▸ | AR | P10275 | 5/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5264649 | 1.00 | MC4R (0.52) | MC4RARUSP2HTTNPSR1 | |
| SCHEMBL9926039 | 0.91 | LMNA (0.52) | MC4RARUSP2HTTNPSR1 | |
| SCHEMBL9926136 | 0.86 | USP2 (0.57) | ARUSP2HTTNPSR1LMNA | |
| SCHEMBL14269767 | 0.86 | USP2 (0.57) | ARUSP2HTTNPSR1LMNA | |
| SCHEMBL9926098 | 0.86 | USP2 (0.57) | ARUSP2HTTNPSR1LMNA | |
| SCHEMBL9926101 | 0.85 | SMN1; SMN2 (0.47) | MC4RARUSP2LMNAMAPT | |
| SCHEMBL4849442 | 0.85 | LMNA (0.48) | ARUSP2HTTLMNAMAPT | |
| SCHEMBL4847578 | 0.85 | LMNA (0.48) | ARUSP2HTTLMNAMAPT | |
| SCHEMBL9925998 | 0.85 | AR (0.46) | MC4RARUSP2MAPT | |
| SCHEMBL5270813 | 0.85 | AR (0.46) | MC4RARUSP2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1836180-B1 | SULFONYL PYRROLIDINES, METHOD FOR PRODUCING THE SAME AND THEIR USE AS DRUGS | SANOFI SA (FR) | 2012-06-13 | — | — | EP | disclosed |
| US-7468369-B2 | Sulfonyl pyrrolidines, method for producing the same and their use as drugs | SANOFI-AVENTIS (FR) | 2008-12-23 | — | — | US | disclosed |
| US-20080045540-A1 | SULFONYL PYRROLIDINES, METHOD FOR PRODUCING THE SAME AND THEIR USE AS DRUGS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045540-A1 | SULFONYL PYRROLIDINES, METHOD FOR PRODUCING THE SAME AND THEIR USE AS DRUGS | SLC5A1, SLC5A2, KCNJ1 | MC4R 1509/4885AR 4287/4885USP2 3511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.